| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | IgG receptor FcRn large subunit p51, FcRn, IgG Fc fragment receptor transporter alpha chain, Neonatal Fc receptor, Fcgrt, Fcrn. |
| Biological Activity | |
| Concentration | |
| Expression System | |
| Form | Sterile Filtered colorless solution. |
| Formulation | |
| Product Type | |
| Protein Length | |
| Protein Size | |
| Purity | |
| Source | HEK293 Cells. |
| Species | |
| Storage | |
| Target |
Recombinant Human Fc Fragment Of IgG Receptor And Transporter is supplied as a recombinant protein for in vitro research use.
Background
Applications in Drug Delivery and Therapy: The unique ability of FCGRT to transport immunoglobulins has spurred investigations into its potential applications in drug delivery. FCGRT Human Recombinant is being explored as a tool to improve the pharmacokinetics of therapeutic antibodies, enhancing their stability and extending their half-life in circulation. This holds significant implications for the development of antibody-based therapies for a range of diseases, including autoimmune disorders and cancer. Modulation of Immune Responses: Beyond its role in immunoglobulin transport, FCGRT is implicated in the modulation of immune responses. FCGRT Human Recombinant studies have unveiled its interactions with immune cells and its potential influence on the activation and regulation of the immune system. This dual role positions FCGRT as a key player not only in passive immunity but also in the dynamic orchestration of immune responses. Challenges and Future Directions: While the potential of FCGRT Human Recombinant in drug delivery is promising, challenges persist. Fine-tuning its applications, understanding its interactions with diverse antibodies, and optimizing strategies for therapeutic use are critical considerations for translational success. Additionally, deciphering the intricate balance between immunoglobulin transport and immune modulation is an active area of investigation. FCGRT Human Recombinant emerges as a sentinel in the realm of immunoglobulin transport and drug delivery, offering a controlled platform for scientific exploration. Its structural insights, immunoglobulin transport functions, and therapeutic applications position it as a key player in the evolving landscape of biopharmaceuticals. As researchers continue to delve into the molecular intricacies of FCGRT, they not only enhance our understanding of immunoglobulin transport but also pave the way for transformative advancements in drug delivery and antibody-based therapies, shaping the future of precision medicine and targeted therapeutics.
Product format
Provided as a recombinant protein suitable for in vitro workflows such as binding studies, screening, and assay development. Refer to the specifications table for expression format and molecular properties.
What is the purity of Recombinant Human Fc Fragment Of IgG Receptor And Transporter (Human)?
What buffer / formulation is this protein supplied in?
How should Recombinant Human Fc Fragment Of IgG Receptor And Transporter (Human) be stored?
What expression system was used to produce this protein?
Is this protein biologically active?
Is this protein approved for clinical or in vitro diagnostic use?
Can I request a custom size, tag variant, or formulation?
Can’t Find What You’re Looking For? We can help you source the best match or customize a recombinant protein solution for your study. Options may include species (human/mouse/rat), protein region/domain (full-length vs fragment), tag or label (His/GST/FLAG/biotin/fluorescent), expression system (E. coli/HEK293/insect), purity grade, formulation (buffer, carrier-free, glycerol-free), activity/functional validation (binding or enzymatic assays), endotoxin level (low-endotoxin for cell-based work), mutants/variants (point mutations, isoforms), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
